EuroSIDA Publications 2026

1. Reply to: HIV-TB risk factor assessment in Europe: methodological considerations and clinical implications. Kraef C, Ryom L, Kirk O; writing group and the RESPOND study group.
   Eur Respir J. 2026;67(3):2502523.  Abstract

2. Cancer burden and risk factors among women with HIV: a multi-regional study from the D:A:D and RESPOND cohort collaborations.  Han WM, Neesgaard B, Knappik M, Cavassini M, Abela IA, Timiryasova A, Greenberg L, Martin C, Mussini C, Wit F, Sabin C, Castagna A, Abutidze A, El-Sadr W, Bonnet F, Sarcletti M, Carlander C, Hachfeld A, Weis N, Vannappagari V, Rogatto FP, Young LA, Hosein SR, Ryom L, Petoumenos K; D:A:D; RESPOND collaborations.
   EClinicalMedicine. 2026;91:103739.  Abstract

3. Trends in AIDS-defining illnesses among people living with HIV in clinical care in Europe: results from the EuroSIDA multicentre cohort study (2003-24). Bannister WP, Reekie J, Peters L, Oprea C, Matulionytė R, Scheerder MA, Kryshchuk A, Rasmussen LD, Burns F, Zilmer K, Jablonowska E, Boesecke C, Zagalo A, Martinez E, Stoeckle M, Szlávik J, Cetkovic JT, Adamis G, Kowalska JD, Podlekareva D; EuroSIDA Study Group.
   Lancet HIV. 2026 May:S2352-3018(26)00052-4. Epub ahead of print.  Abstract